A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible fo

Brief description of study

This study looks at two treatments (TAR-200 + IV cetrelimab versus IV cetrelimab alone) for a specific kind of bladder cancer (muscle-invasive bladder cancer unsuitable for platinum-based neoadjuvant therapy). We want to see how well these treatments work before surgery. The main thing we're checking is if the cancer completely goes away. We also care about having few side effects and how long it takes for the cancer to come back after treatment. Patients in the study will be put into groups by chance and get one of two treatments. They'll have some tests before joining to make sure they're eligible for the study. A group of trained staff will watch over the study to make sure everything goes well.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.